[CAS NO. 126-27-2] Oxethazaine

Name: Oxethazaine
Brand: Arctom Scientific
SKU: HY-B0955

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [126-27-2]

Distributor

Catalog

HY-B0955

Brand

MCE

CAS

126-27-2

DESCRIPTION [126-27-2]

Overview

MDL	MFCD00079202
Molecular Weight	467.64
Molecular Formula	C28H41N3O3
SMILES	OCCN(CC(N(C(C)(C)CC1=CC=CC=C1)C)=O)CC(N(C(C)(C)CC2=CC=CC=C2)C)=O

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]Stem Cell Res Ther. 2021 Feb 4;12(1):107.

Summary

Oxethazaine (Oxetacaine), a precursor of phentermine acidic, is an acid-resistent and orally active analgesic agent . Oxethazaine (Oxetacaine) has the potential for the relief of pain associated with peptic ulcer disease or esophagitis ^[1] .

In Vivo

Oxetacaine (intraperitoneal injection; 5, 10, and 15 mg/kg; during days 4–11) doses induces significant conditioned place preference (CPP), and there are no differences among the groups. While its postive control group phentermine only 3 mg/kg causes significant CPP ^[1] .
.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats ^[1]
Dosage:	5, 10, and 15 mg/kg; during days 4–11
Administration:	Intraperitoneal injection
Result:	Showed a significant CPP in vivo.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01336530	MEDA Pharma GmbH & Co. KG\|Trium Analysis Online GmbH\|ICON plc\|Clinipace Worldwide\|Viatris Inc.	Radiation-induced Oesophagitis	April 2011	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL ( 106.92 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1384 mL	10.6920 mL	21.3840 mL
5 mM	0.4277 mL	2.1384 mL	4.2768 mL
10 mM	0.2138 mL	1.0692 mL	2.1384 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: 2.5 mg/mL (5.35 mM); Suspended solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.35 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.35 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Acetamide, 2,2′-[(2-hydroxyethyl)imino]bis[N-(1,1-dimethyl-2-phenylethyl)-N-methyl-

Acetamide, 2,2′-[(2-hydroxyethyl)imino]bis[N-(α,α-dimethylphenethyl)-N-methyl-

2,2′-[(2-Hydroxyethyl)imino]bis[N-(1,1-dimethyl-2-phenylethyl)-N-methylacetamide]

FH 099

Wy 806

Betalgil

2-Di(N-methyl-N-phenyl-tert-butyl-carbamoylmethyl)aminoethanol

2,2′-[(2-Hydroxyethyl)imino]bis[N-(α,α-dimethylphenethyl)-N-methylacetamide]

Oxaine

Oxethazaine

Mucoxin

Oxetacaine

Storocain

Storocaine

Topicain

2-[2-Hydroxyethyl-[2-[methyl-(2-methyl-1-phenylpropan-2-yl)amino]-2-oxoethyl]amino]-N-methyl-N-(2-methyl-1-phenylpropan-2-yl)acetamide